FORT WORTH, Texas, Sept. 28 /PRNewswire/ -- HEALTHPOINT Ltd. has announced that ACCUZYME(R) (Papain, Urea) Ointment, its popular pharmaceutical product for wound debriding, is now available in a new pump-spray delivery system, ACCUZYME Spray, on which a patent application is pending.
ACCUZYME Spray is HEALTHPOINT’s second product to feature the unique, non-aerosol, spray delivery. PANAFIL (Papain, Urea, Chlorophyllin Copper Complex Sodium) Spray, from HEALTHPOINT, arrived on the market in February, and the wound healing, debriding and deodorizing product has quickly gained a following.
Until now, ACCUZYME has been available only as an ointment that requires the use of a manual applicator. The new liquid-spray formulation of ACCUZYME allows for smooth, even application on a wound bed. The spray bottle is easy to maneuver, making it possible for ACCUZYME to reach areas of a wound that otherwise might receive inadequate coverage.
“This new delivery system for ACCUZYME Spray is a great benefit both to the patient with a wound that needs to be debrided, and to that patient’s caregiver,” said Sherlene Bagley, HEALTHPOINT’s product director for ACCUZYME Spray. “It allows for more controlled and uniform delivery of ACCUZYME, particularly on a moist wound bed, without running or dripping. This means that less ACCUZYME is needed each time a wound is treated, which can translate into a significant cost savings if a wound requires multiple debridement treatments.”
Health care providers in thousands of hospitals, wound-care centers and long-term care facilities, as well as home-health workers and patients themselves have used ACCUZYME (Papain, Urea) Ointment with great success for debridement of acute and chronic wounds such as pressure, varicose and diabetic ulcers; postoperative wounds; and burns and other wounds resulting from injury. ACCUZYME Spray, like ACCUZYME Ointment, is indicated for debridement of necrotic tissue and liquefaction of slough in acute and chronic wounds. There are two active ingredients in ACCUZYME Spray: Papain, the proteolytic enzyme from the fruit of carica papaya, is a potent digestant of noviable protein matter, harmless to viable tissue, and active over a pH range of 3 to 12; and urea, a water-soluble compound that is the major nitrogenous end product of protein metabolism and is a denaturant of proteins. Both work to remove from the wound bed non-viable proteins that impede healing.
The spray permits the product to be applied to a wound without the direct contact of a cotton swab or tongue depressor, thus minimizing waste, mess, possible infection and trauma to the patient. Cost savings are achieved through a reduced need for supplies and an increase in the number of applications that can be administered per 33mL bottle of spray when compared to a 30-gram tube of ointment.
A controlled study was conducted recently to assess the end-use clinical application of the new spray when compared to the conventional ointment form. Results showed that less time was required for the spray to be administered than for the ointment, and that less material was consumed.
“ACCUZYME has always been a fast debrider, but now it’s even faster -- and more accurate -- thanks to this easy-to-use spray delivery system,” Bagley said. “Beyond the cost containment that’s implied by the accuracy of the spray, we see it resulting in even greater acceptance by patients and clinicians because it is so easy to use.”
ACCUZYME Spray is available by prescription only in a 33-milliliter spray bottle. ACCUZYME Ointment, also available by prescription only, comes in 30-gram or 6-gram tubes. ACCUZYME is generally well-tolerated and nonirritating. However, upon application, a small number of patients may experience a brief stinging sensation.
“After the launch of PANAFIL Spray earlier this year, clinicians across the country began asking for the same delivery form for ACCUZYME Ointment,” said Dwayne Dixon, director of marketing for wound preparation and healing at HEALTHPOINT. “We’re proud that we could respond quickly to bring this technology to another product in the HEALTHPOINT family of wound pharmaceuticals and biologics.”
Since its inception in 1992, HEALTHPOINT has established a U.S. presence in the research, development and marketing of branded pharmaceuticals, biologics and over-the-counter drugs and medical devices for tissue management, dermatology and surgical applications. An aggressive research and development effort has brought HEALTHPOINT’s unique technologies to the market, setting the pace for its highly trained field sales organization of direct sales representatives. HEALTHPOINT, with more than 250 employees, is a DFB Pharmaceuticals, Inc. affiliate company. Visit HEALTHPOINT’s Web site at http://www.healthpoint.com/ .
DFB, through its affiliate companies, contract partners and branded marketing organizations, provides technology-driven products, outsourcing services and in-licensing and out-licensing opportunities to the health care industry worldwide.
HEALTHPOINT has headquarters in Fort Worth, Texas, with additional offices in Canada. Visit HEALTHPOINT’s Web site at http://www.healthpoint.com/ .
HEALTHPOINT Ltd.
CONTACT: David Doremus, +1-817-335-1373, or doremus@witherspoon.com ,for HEALTHPOINT Ltd.
Web site: http://www.healthpoint.com/
